[Chinese Expert Consensus on Antiangiogenic Drugs for Advanced Non-small Cell Lung Cancer (2019 Edition)].
出版信息
Zhongguo Fei Ai Za Zhi. 2019 Jul 20;22(7):401-412. doi: 10.3779/j.issn.1009-3419.2019.07.01.
Abstract
摘要
相似文献
1
[Chinese Expert Consensus on Antiangiogenic Drugs for Advanced Non-small Cell Lung Cancer (2019 Edition)].
Zhongguo Fei Ai Za Zhi. 2019 Jul 20;22(7):401-412. doi: 10.3779/j.issn.1009-3419.2019.07.01.
2
[Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2020 Edition)].
Zhonghua Zhong Liu Za Zhi. 2020 Dec 23;42(12):1063-1077. doi: 10.3760/cma.j.cn112152-20200918-00836.
3
[Chinese Expert Consensus on Next Generation Sequencing Diagnosis
for Non-small Cell Lung Cancer (2020 Edition)].
Zhongguo Fei Ai Za Zhi. 2020 Sep 20;23(9):741-761. doi: 10.3779/j.issn.1009-3419.2020.101.45.
4
[Expert Consensus on Adjuvant Therapy of Non-small Cell Lung Cancer from China Thoracic Surgeons (2018 Version)].
Zhongguo Fei Ai Za Zhi. 2018 Oct 20;21(10):731-737. doi: 10.3779/j.issn.1009-3419.2018.10.01.
5
The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis.
Clin Lung Cancer. 2017 May;18(3):255-258. doi: 10.1016/j.cllc.2016.12.001. Epub 2017 Jan 5.
6
Current and future strategies for antiangiogenic agents in non-small-cell lung cancer.
Clin Lung Cancer. 2008 Mar;9 Suppl 2:S50. doi: 10.3816/CLC.2008.s.007.
7
Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience.
Ther Adv Respir Dis. 2016 Oct;10(5):485-91. doi: 10.1177/1753465816652083. Epub 2016 Jun 23.
8
Effects of microRNA regulation on antiangiogenic therapy resistance in non-small cell lung cancer.
Biomed Pharmacother. 2020 Nov;131:110557. doi: 10.1016/j.biopha.2020.110557. Epub 2020 Aug 21.
9
[Angiogenesis and neoangiogenesis--the role in lung cancer and other tumors].
Pneumonol Alergol Pol. 2006;74(4):414-20.
10
Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.
Expert Rev Anticancer Ther. 2013 Oct;13(10):1193-206. doi: 10.1586/14737140.2013.845093.
引用本文的文献
1
Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway.
Front Pharmacol. 2024 Jul 31;15:1405521. doi: 10.3389/fphar.2024.1405521. eCollection 2024.
2
LncRNA MRPL39 inhibits cell proliferation and migration by regulating miR-130/TSC1 axis in non-small cell lung cancer.
3 Biotech. 2024 May;14(5):125. doi: 10.1007/s13205-024-03975-y. Epub 2024 Apr 2.
3
Insights into the pleiotropic roles of ZNF703 in cancer.
Heliyon. 2023 Sep 14;9(9):e20140. doi: 10.1016/j.heliyon.2023.e20140. eCollection 2023 Sep.
4
Dysregulation of Pseudogenes/lncRNA-Hsa-miR-1-3p-PAICS Pathway Promotes the Development of NSCLC.
J Oncol. 2022 Aug 30;2022:4714931. doi: 10.1155/2022/4714931. eCollection 2022.
5
Plasma D-Dimer Level Correlates with Age, Metastasis, Recurrence, Tumor-Node-Metastasis Classification (TNM), and Treatment of Non-Small-Cell Lung Cancer (NSCLC) Patients.
Biomed Res Int. 2021 Oct 19;2021:9623571. doi: 10.1155/2021/9623571. eCollection 2021.
6
[Research Progress of Anti-angiogenic Agents Combined with Immunotherapy
in Patients with Advanced Non-small Cell Lung Cancer].
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):196-203. doi: 10.3779/j.issn.1009-3419.2021.101.05.
本文引用的文献
1
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
2
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8.
3
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Lancet Respir Med. 2019 May;7(5):387-401. doi: 10.1016/S2213-2600(19)30084-0. Epub 2019 Mar 25.
4
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
5
Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer.
Thorac Cancer. 2018 Jul;9(7):805-813. doi: 10.1111/1759-7714.12650. Epub 2018 May 16.
6
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
J Clin Oncol. 2018 Jun 10;36(17):1675-1684. doi: 10.1200/JCO.2017.77.0412. Epub 2018 Mar 23.
7
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
Br J Cancer. 2018 Mar 6;118(5):654-661. doi: 10.1038/bjc.2017.478. Epub 2018 Feb 13.
8
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics.
Semin Cancer Biol. 2018 Oct;52(Pt 2):117-124. doi: 10.1016/j.semcancer.2017.12.002. Epub 2017 Dec 8.
9
Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?
Crit Rev Oncol Hematol. 2017 Nov;119:30-39. doi: 10.1016/j.critrevonc.2017.09.007. Epub 2017 Sep 19.
10
Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.
Drug Saf. 2018 Feb;41(2):229-237. doi: 10.1007/s40264-017-0596-0.
Zotero 插件